TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Telomir Pharmaceuticals, Inc., a Florida-based biopharmaceutical company, has announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor, effective August 28, 2024. Dr. Angel, with over 30 years of industry experience and former Head of Pharmacology at Synthelabo (now part of Sanofi-Aventis), is set to lead the company's regulatory submissions for their novel small molecule, Telomir-1.
Telomir-1 is designed to lengthen telomeres, the protective caps of DNA, and holds promise for treating progeria, a rare genetic disorder characterized by accelerated aging. The company is considering applying for orphan drug status to expedite the drug's approval process for human use.
For veterinary applications, Telomir Pharmaceuticals is exploring the possibility of obtaining Minor Use and Minor Species (MUMS) designation, which could benefit treatments for less common conditions in major species such as dogs.
Dr. Angel's previous contributions to the pharmaceutical industry include the development of drugs like Xatral, Ambien, and Mizollen. His expertise is expected to guide Telomir Pharmaceuticals through the Investigational New Drug (IND) and Investigational New Animal Drug (INAD) application processes.
The company's pursuit of these regulatory pathways reflects their commitment to exploring Telomir-1's potential across both human and veterinary medicine. Ongoing research and studies are being conducted to further understand the molecule's capabilities, with Dr. Angel at the helm of navigating the regulatory landscape.
In other recent news, Telomir Pharmaceuticals has reported significant health improvements in two senior dogs treated with their novel small molecule, Telomir-1. The dogs, part of a compassionate use program, showed potential benefits for age-related conditions. Telomir-1 remains in preclinical development, and the company has stated there is no assurance it will receive FDA approval for marketing.
On the corporate side, Telomir Pharmaceuticals has named Michelle Yanez as the new Chief Financial Officer, succeeding Nathan Fuentes. Yanez brings in over 25 years of financial experience in the biotech and pharmaceutical sectors.
The company has also initiated a key study on the safety of Telomir-1 in geriatric canines. Concurrently, Telomir-1 is being administered to a 12-year-old German Shepherd, providing additional insights for the company's future research strategies.
Finally, Telomir Pharmaceuticals has partnered with Argenta to conduct a study evaluating Telomir-1's efficacy in addressing canine osteoarthritis, a condition affecting nearly 18 million dogs in the United States. These are among the recent developments at Telomir Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.